Cor Vasa 2009, 51(2):112-117 | DOI: 10.33678/cor.2009.028

Antithrombotic therapy after acute myocardial infarction

Ota Hlinomaz
I. interní kardioangiologická klinika, Fakultní nemocnice u sv. Anny v Brně a Lékařská fakulta Masarykovy univerzity, Brno, Česká republika

Antithrombotics are basic agents for the prevention and treatment of acute coronary syndromes. They are divided into antiplatelet and anticoagulant agents. The most important oral agents are acetylosalicylic acid, clopidogrel and warfarin. Novel antithrombotics such as prasugrel, ticagrelor, rivaroxaban and dabigatran seem to be promising. The vast majority of patients after acute myocardial infarction should be treated with aspirin plus clopidogrel for 12 months unless there is an excessive risk of bleeding or a contraindication.

Keywords: Acute myocardial infarction; Antithrombotic therapy; Antiplatelet therapy; Clopidogrel

Published: February 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hlinomaz O. Antithrombotic therapy after acute myocardial infarction. Cor Vasa. 2009;51(2):112-117. doi: 10.33678/cor.2009.028.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hirsch J. Guidelines for antithrombotic therapy. 8th ed. Hamilton: BC Decker Inc, 2008:20.
    2. Patrono C, Coller B, Dalen JE, et al. Platelet-Active Drugs: The relathionships among dose, effectiveness, and side effects. Chest 2001;119:395-693. Go to original source... Go to PubMed...
    3. Antithrombotic Trialists' Collaboration. Prevention of death, myocardial infarction and stroke by antiplatelet therapy in high-risk patients. Br Med J 2002;324:71-86. Go to original source...
    4. Malý J. Rezistence na kyselinu acetylosalicylovou. Interv Akut Kardiol 2005;4:192-3.
    5. The Task Force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. Eur Heart J 2004;25:166-81.
    6. Bassand JP, Hamm CW, Ardissino D, et al. The Task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660. Go to original source... Go to PubMed...
    7. Bělohlávek J, Aschermann M. Doporučený postup pro diagnostiku a léčbu akutních koronárních syndromů bez elevací úseků ST na EKG. Cor Vasa 2008;50 (Suppl):S7-S23.
    8. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008;29:2909-45.
    9. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39. Go to original source...
    10. Widimský P. Perspektivy protidestičkové léčby: třetí vzadu se směje. Cor Vasa 2005;47:123-4.
    11. Yusuf S, Zhao F, Mehta ST, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. Go to original source... Go to PubMed...
    12. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33. Go to original source...
    13. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20. Go to original source... Go to PubMed...
    14. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fybrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-32. Go to original source... Go to PubMed...
    15. Tejc M, Hlinomaz O. Nová data o clopidogrelu - studie CLARITY-TIMI 28, COMMIT-CCS2 a ARMYDA-2. Interv Akut Kardiol 2005;4:154-8.
    16. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005;45:1157-64. Go to original source... Go to PubMed...
    17. Kumbhani DJ. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent stent thrombosis (VASP guided PCI). Presented at AHA 2008. New Orleans. www.cardiosource.com.
    18. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15. Go to original source... Go to PubMed...
    19. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes. Circulation 2000;102:149-56. Go to original source...
    20. The Symphony Investigators. Sibrafiban vs Aspirin to yield maximum protection from ischemic heart events post acute coronary syndromes. Lancet 2000;355:337-45. Go to original source...
    21. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74. Go to original source... Go to PubMed...
    22. Andreotti F, Testa L, Biondi-Zoccai GG, et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients. Eur Heart J 2006;27: 519-26. Go to original source... Go to PubMed...
    23. Studenčan M. Akutní koronární syndrom. Košice: Sport Media Group, 2007:145-51.
    24. Varvařovský I, Matějka J. Antitrombotická léčba akutních koronárních syndromů. Praha: Galén, 2008:111-62.
    25. Agnelli G, Gallus A, Goldhaber SZ, et al, on behalf of the ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study. Circulation 2007;116:180-7. Go to original source... Go to PubMed...
    26. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007;5 Suppl 1:60-4. Go to original source... Go to PubMed...
    27. Gibson CM, Mega JL, Hammett CJ, et al. Anti-Xa therapy to lower cardiovascular events in addition to aspirin with or without thienopyridine therapy in subjects with acute coronary syndrome -TIMI 46 trial. Presented at AHA 2008. New Orleans: www.cardiosource.com.
    28. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007;116:552-60. Go to original source... Go to PubMed...
    29. Eikelboom JW, Weitz JI. A replacement for warfarin. The search continues. Circulation 2007;116:552-60. Go to original source... Go to PubMed...
    30. Friedewald VE, Bates ER, Granger CB, Yusuf S, Roberts WC. The Editor's Roundtable: arterial thrombosis and acute coronary syndromes. Am J Cardiol 2007;100:974-80. Go to original source... Go to PubMed...
    31. Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 2007;39:371-91. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes